DUBLIN--(BUSINESS WIRE)-- The "Sarcoma Drugs Market Size, Share & Trends Analysis Report By Treatment Type (Chemotherapy, Targeted Therapy), By Major Markets (U.S., U.K., Germany, Spain, Italy, France, Japan), And Segment Forecasts, 2018 - 2023" report has been added to ResearchAndMarkets.com's offering.

The global sarcoma drugs market size is expected to be valued at USD 1.2 billion by 2023, progressing at a CAGR of 8.5% during the forecast period.

The growth of the market is largely driven by factors such as new product launches, increasing adoption of novel therapeutics, and growing target population.

Sarcomas account for less than 1.0% of all adult cancers. Though sarcomas represent a heterogeneous group of over 50 different histological subtypes, the two major subtypes are soft tissue sarcomas (STS) and bone sarcoma. Approximately, 12,000 patients in the U.S. and 28,000 patients in Europe are diagnosed with STS every year.

For over 40 years, mainstay of localized sarcoma treatment included surgical resection followed by neoadjuvant or adjuvant radiation or chemotherapy. However, even after complete surgical resection, about 50.0% of patients with intermediate or high grade sarcoma develop metastatic disease. Introduction of targeted therapy has revolutionized treatment paradigm for sarcoma. Targeted therapies and pipeline breakthroughs will continue to play a pivotal role in the growth of the market throughout the forecast period.

Key Topics Covered:

Chapter 1 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology

Chapter 4 Global Sarcoma Drugs Market Overview

Chapter 5 Sarcoma Drugs Market: Pipeline Intelligence

Chapter 6 Company Profiles

• Novartis
• Pfizer
• Eli Lilly
• Eisai
• Johnson & Johnson
• Bayer

For more information about this report visit https://www.researchandmarkets.com/research/tz3sxt/global_sarcoma?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181101005715/en/

Report Abuse